ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
AstraZeneca, Nestlé Health Science, and Bayer CropScience have independently formed strategic partnerships with Cambridge, Mass.-based Flagship Ventures, a venture capital firm. Flagship is focused on investing in the fields of health care and sustainable technology. As part of their agreements with Flagship, the three partners have made financial investments in Flagship Ventures’ Fund V, a $537 million venture capital fund. Flagship says the partnerships will enable it to scale up VentureLabs, its hothouse for starting up and fostering technology companies. Start-ups that have emerged from VentureLabs include biotech firms Moderna Therapeutics and Seres Health, as well as bioenergy firm Joule Unlimited.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X